blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3800270

EP3800270 - INHIBITORS OF MET AND IGSF1 FOR TREATING GASTRIC AND LUNG CANCER [Right-click to bookmark this link]
Former [2021/14]NOVEL BIOMARKER FOR PREDICTING SENSITIVITY TO MET INHIBITOR, AND USE THEREOF
[2021/29]
StatusNo opposition filed within time limit
Status updated on  02.09.2022
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  24.09.2021
FormerGrant of patent is intended
Status updated on  27.06.2021
FormerRequest for examination was made
Status updated on  21.05.2021
FormerThe application has been published
Status updated on  05.03.2021
Most recent event   Tooltip27.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 30.10.2024 [2024/44]
Applicant(s)For all designated states
Wellmarker Bio Co., Ltd.
11th Fl., 88, Olympic-ro 43-gil
Songpa-gu, Seoul 05505 / KR
[2021/14]
Inventor(s)01 / JIN, Dong Hoon
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil
138-736 Seoul / KR
02 / HONG, Seung Woo
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil
138-736 Seoul / KR
03 / MOON, Jai Hee
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil
138-736 Seoul / KR
04 / SHIN, Jae Sik
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil, Songpa-gu
138-736 Seoul / KR
05 / KIM, Seung Mi
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil, Songpa-gu
138-736 Seoul / KR
06 / LEE, Dae Hee
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil, Songpa-gu
138-736 Seoul / KR
07 / LEE, Eun Young
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil, Songpa-gu
138-736 Seoul / KR
08 / LEE, Seul
5F Convergence-innovation building
Asan Institute for Life Science
Asan Medical Center
88 Olympicro-43gil, Songpa-gu
138-736 Seoul / KR
 [2021/14]
Representative(s)Cabinet Laurent & Charras
Le Contemporain
50 Chemin de la Bruyère
69574 Dardilly Cedex / FR
[2021/14]
Application number, filing date20207150.229.07.2015
[2021/14]
Priority number, dateKR2014009663629.07.2014         Original published format: KR 20140096636
[2021/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3800270
Date:07.04.2021
Language:EN
[2021/14]
Type: B1 Patent specification 
No.:EP3800270
Date:27.10.2021
Language:EN
[2021/43]
Search report(s)(Supplementary) European search report - dispatched on:EP26.02.2021
ClassificationIPC:C12Q1/68, A61K31/7088, A61P35/00
[2021/14]
CPC:
A61K31/404 (EP,US); C12Q1/6886 (US); A61K31/7088 (EP,US);
A61K31/713 (EP,US); A61P1/04 (EP); A61P11/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP);
C12N15/1138 (US); C12Q1/68 (EP,US); C12Y207/10001 (EP,US);
G01N33/574 (US); G01N33/57492 (US); C12N2310/14 (US);
C12N2310/141 (US); C12N2310/531 (US); C12N2320/31 (US);
C12Q2600/106 (US); C12Q2600/158 (US); G01N2333/70503 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/25]
Former [2021/14]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:INHIBITOREN VON MET UND IGSF1 ZUR BEHANDLUNG VON MAGEN- UND LUNGENKREBS[2021/29]
English:INHIBITORS OF MET AND IGSF1 FOR TREATING GASTRIC AND LUNG CANCER[2021/29]
French:INHIBITEURS DE MET ET IGSF1 POUR LE TRAITEMENT DU CANCER DU POUMON ET DE L'ESTOMAC[2021/29]
Former [2021/14]NEUARTIGER BIOMARKER ZUR VORHERSAGE DER EMPFINDLICHKEIT AUF EINEN MET-INHIBITOR UND VERWENDUNG DAVON
Former [2021/14]NOVEL BIOMARKER FOR PREDICTING SENSITIVITY TO MET INHIBITOR, AND USE THEREOF
Former [2021/14]NOUVEAU BIOMARQUEUR POUR PRÉDIRE LA SENSIBILITÉ À UN INHIBITEUR MET ET UTILISATION CORRESPONDANTE
Examination procedure18.05.2021Examination requested  [2021/25]
18.05.2021Date on which the examining division has become responsible
28.06.2021Communication of intention to grant the patent
16.09.2021Fee for grant paid
16.09.2021Fee for publishing/printing paid
16.09.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15828125.3  / EP3176269
Opposition(s)28.07.2022No opposition filed within time limit [2022/40]
Fees paidRenewal fee
12.11.2020Renewal fee patent year 03
12.11.2020Renewal fee patent year 04
12.11.2020Renewal fee patent year 05
12.11.2020Renewal fee patent year 06
26.07.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.07.2015
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
MT27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
TR27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
[2024/44]
Former [2024/29]HU29.07.2015
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
TR27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2024/26]HU29.07.2015
AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2024/23]AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
MK27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2024/20]AL27.10.2021
AT27.10.2021
CY27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2023/11]AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
MC27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/49]AL27.10.2021
AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/35]AT27.10.2021
CZ27.10.2021
DK27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SK27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/34]AT27.10.2021
EE27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RO27.10.2021
RS27.10.2021
SE27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/33]AT27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RS27.10.2021
SE27.10.2021
SM27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/25]AT27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RS27.10.2021
SE27.10.2021
BG27.01.2022
NO27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/24]AT27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
NL27.10.2021
PL27.10.2021
RS27.10.2021
SE27.10.2021
BG27.01.2022
GR28.01.2022
IS27.02.2022
PT28.02.2022
Former [2022/23]AT27.10.2021
FI27.10.2021
HR27.10.2021
LT27.10.2021
LV27.10.2021
PL27.10.2021
RS27.10.2021
BG27.01.2022
PT28.02.2022
Former [2022/22]AT27.10.2021
FI27.10.2021
LT27.10.2021
RS27.10.2021
BG27.01.2022
Former [2022/21]AT27.10.2021
RS27.10.2021
BG27.01.2022
Former [2022/19]BG27.01.2022
Documents cited:Search[A]WO2005095622  (VAN ANDEL RES INST [US], et al) [A] 1-5* the whole document *;
 [A]US2012100157  (VANDE WOUDE GEORGE F [US], et al) [A] 1-5 * paragraph [0010] - paragraph [0011] *;
 [A]WO2012119113  (NESTEC SA [CH], et al) [A] 1-5 * paragraph [0077] *;
 [A]WO2012178128  (ONCOCYTE CORP [US], et al) [A] 1-5 * paragraph [0226] *;
 [A]  - S. T. YOUNGER ET AL, "Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters", NUCLEIC ACIDS RESEARCH, (20110322), vol. 39, no. 13, doi:10.1093/nar/gkr155, ISSN 0305-1048, pages 5682 - 5691, XP055007870 [A] 1-5 * abstract *

DOI:   http://dx.doi.org/10.1093/nar/gkr155
by applicant   - WEINSTEIN-OPPENHEIMER et al., Pharma. . Therap., (20000000), vol. 88, pages 229 - 279
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.